You are leaving this site You are about to leave www.grantformultiplesclerosisinnovation.org/. The content of the site you are about to visit is not controlled by www.grantformultiplesclerosisinnovation.org/.
EMD Serono Inc.–the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the United States– is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and multiple sclerosis. Today, the business has approximately 1300 employees around the country, with commercial, clinical and research operations based in the company's home state of Massachusetts.
For more information, please visit www.emdserono.com.
EMD Serono, Canada is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany. EMD Serono, Canada has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono, Canada has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono, Canada has more than 100 employees across Canada, with headquarters in Mississauga, Ontario.
For more information, please visit www.emdserono.ca.
To learn more about other Grants for Innovation in other therapeutic areas, please visit: https://www.emdgroup.com/en/research/grants-and-awards.html